Eli Lilly's Mounjaro could become one of the world's biggest drugs ever

Demand for the diabetes medicine is already big, and the US-based company is also expected to apply for market authorization in the obesity indication. (Updated)


Eli Lilly could potentially have the world’s best-selling drug ever, reports Dow Jones citing an analysis from UBS on Thursday.

The hailed drug, Mounjaro (tirzepatide), is a direct competitor of Novo Nordisk’s most lucrative product, type 2 diabetes medicine Ozempic, and could also be a potential challenger of the Danish drugmaker’s sought-after anti-obesity drug, Wegovy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs